通过ParkinsonNet提供的专科物理治疗的有效性与成本:基于医疗索赔数据的回顾性分析
该研究回顾性分析2013至2015年荷兰帕金森病患者医疗保险索赔数据,比较专科物理治疗(ParkinsonNet模式)与常规物理治疗的长期效果。结果显示,接受专科物理治疗的患者帕金森病相关并发症比例更低(17% vs 21%,OR 0·67,95%CI 0·56-0·81,p<0·0001),且直接成本和总医疗成本均更低。
要点
- 专科物理治疗与更少的帕金森病相关并发症相关(17% vs 21%)。
- 专科物理治疗直接成本更低(年均差€395,95%CI 358-432)。
- 神经科医生可通过转诊至专科物理治疗师促进此类治疗。
核心结论
- 真实世界实践中,通过ParkinsonNet提供的专科物理治疗与更少的帕金森病相关并发症和更低成本相关。
研究设计与样本
- 观察性研究,回顾性分析荷兰帕金森病患者医疗保险索赔数据库,随访至3年(2013年1月1日至2015年12月31日)。
- 共分析2129例接受专科物理治疗的患者(4649次观察)和2252例接受常规物理治疗的患者(5353次观察)。
主要发现
- 专科物理治疗组发生帕金森病相关并发症的患者比例显著更低(368例[17%] vs 480例[21%];OR 0·67,95%CI 0·56-0·81,p<0·0001)。
- 专科物理治疗师年均患者负荷更高(平均3·89例/治疗师[SD 3·91] vs 1·48[1·24])。
- 专科物理治疗组治疗次数更少(平均33·72[SD 26·70] vs 47·97[32·11])。
- 直接成本更低(平均€933[SD 843] vs €1329[1021];年均差€395,95%CI 358-432,p<0·0001)。
- 总医疗成本更低(€2056[3272] vs €2586[3756];差€530,95%CI 391-669,p<0·0001)。
关键数值与推荐
- 纳入标准:诊断为帕金森病且因该病接受物理治疗。
- 主要结局:调整基线变量后帕金森病相关并发症(因骨折、其他骨科损伤或肺炎就诊或住院)的患者百分比。
临床怎么用
- 神经科医生可通过具体转诊至专科物理治疗师来促进专科物理治疗。
局限性
- 观察性研究设计,分组基于患者和转诊医生的选择,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parkinson's disease is a complex condition that is best managed by specialised professionals. Trials show that specialised allied health interventions are cost-effective, as compared with usual care. We aimed to study the long-term benefits of specialised physiotherapy using the ParkinsonNet approach in real-world practice. METHODS: We did an observational study, retrospectively analysing a database of health insurance claims that included a representative population of Dutch patients with Parkinson's disease, who were followed for up to 3 years (Jan 1, 2013, to Dec 31, 2015). Eligibility criteria included having both a diagnosis of Parkinson's disease and having received physiotherapy for the disease. Allocation to specialised or usual care physiotherapy was based on the choices of patients and referring physicians. We used a mixed-effects model to compare health-care use and outcomes between patients treated by specialised or usual care physiotherapists. The primary outcome was the percentage of patients with a Parkinson's disease-related complication (ie, visit or admission to hospital because of fracture, other orthopaedic injuries, or pneumonia) adjusted for baseline variables. We compared physiotherapist caseload, the number of physiotherapy sessions, physiotherapy costs, and total health-care costs (including hospital care, but excluding community care, long-term care, and informal care) between the groups, and used a Cox's proportional hazard model for survival time to establish whether mortality was influenced by treatment by a specialised physiotherapist. FINDINGS: We analysed 2129 patients (4649 observations) receiving specialised physiotherapy and 2252 patients (5353 observations) receiving usual care physiotherapy. Significantly fewer patients treated by a specialised physiotherapist had a Parkinson's disease-related complication (n=368 [17%]) than patients treated by a usual care physiotherapist (n=480 [21%]; odds ratio 0·67, 95% CI 0·56-0·81, p<0·0001). The annual caseload of patients per therapist was significantly higher for specialised physiotherapists (mean 3·89 patients per therapist [SD 3·91]) than usual care physiotherapists (1·48 [1·24]). Patients who saw specialised physiotherapists received fewer treatment sessions (mean 33·72 [SD 26·70]) than usual care physiotherapists (47·97 [32·11]). Consequently, expenditure was lower for specialised than usual care physiotherapists, both for direct costs (mean €933 [SD 843] vs €1329 [1021]; annual difference €395, 95% CI 358-432, p<0·0001) and total health-care expenditure (€2056 [3272] vs €2586 [3756]; €530, 391-669, p<0·0001). Mortality risk was lower for patients receiving specialised physiotherapy (134 [6%]) compared with patients receiving usual care physiotherapy (205 [9%], p=0·001) before correction for baseline variables, although Cox's survival model showed no significant difference between the two (hazard ratio 0·86, 95% CI 0·69-1·07, p=0·195). INTERPRETATION: These results confirm the findings from controlled trials, and offer evidence that specialised physiotherapy as delivered through ParkinsonNet is associated with fewer Parkinson's disease-related complications and lower costs in real-world practice. Neurologists can facilitate specialised physiotherapy by specific referral to such experts. FUNDING: None.
引用
- Ypinga JHL, de Vries NM, Boonen LHHM, et al. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol. 2017. PMID: 29246470. doi:10.1016/S1474-4422(17)30406-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。